AbCellera Biologics Inc. (ABCL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ABCL currently has 298M outstanding shares. with limited dilution risk as only 56.7M additional shares (19.1%) are authorized for issuance. The company has minimally diluted shareholders by 4.58% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 11, 2026 |
10-Q filing | 297.7M shares outstanding |
300M | 57M |
| Nov 06, 2025 |
10-Q filing | 294.9M shares outstanding |
290M | 57M |
| Aug 07, 2025 |
10-Q filing | 294.2M shares outstanding |
290M | 57M |
| May 08, 2025 |
10-Q filing | 292.7M shares outstanding |
290M | 57M |
| Feb 27, 2025 |
10-K filing | 285.1M shares outstanding |
290M | 57M |
| Nov 04, 2024 |
10-Q filing | 289.5M shares outstanding |
290M | 57M |
| Aug 06, 2024 |
10-Q filing | 288.9M shares outstanding |
290M | 57M |
| May 07, 2024 |
10-Q filing | 287.8M shares outstanding |
290M | 57M |
| Feb 20, 2024 |
10-K filing | 275.8M shares outstanding |
280M | 57M |
| Nov 02, 2023 |
10-Q filing | 285.3M shares outstanding |
290M | 57M |
| Aug 03, 2023 |
10-Q filing | 284.7M shares outstanding |
280M | 57M |
| May 04, 2023 |
10-Q filing | 283.9M shares outstanding |
280M | 57M |
| Feb 21, 2023 |
10-K filing | 263.1M shares outstanding |
260M | 57M |
| Nov 08, 2022 |
10-Q filing | 278.9M shares outstanding |
280M | 57M |
| Aug 09, 2022 |
10-Q filing | 272.2M shares outstanding |
270M | 57M |
| Jul 22, 2022 |
POS AM filing: This is a post-effective amendment to a registration statement on Form S-3 filed by AbCellera Biologics Inc. to replace the consents of independent registered public accounting firms. |
270M | 57M |
| May 10, 2022 |
10-Q filing | 269.7M shares outstanding |
270M | 57M |
| Feb 25, 2022 |
POS AM filing: This POS AM filing registers 12,000,000 common shares for sale by selling shareholders. The company will not receive any proceeds from the sale of shares. |
280M | 57M |
| Feb 25, 2022 |
10-K filing | 283.9M shares outstanding |
280M | 57M |
| Nov 10, 2021 |
10-Q filing | 281.6M shares outstanding |
280M | 69M |
| Aug 13, 2021 |
10-Q filing | 260.8M shares outstanding |
260M | 69M |
| Jun 10, 2021 |
S-1 filing: This S-1 filing relates to the offer and sale of up to 12,000,000 common shares of AbCellera Biologics Inc. by the selling shareholders. |
270M | 69M |
| May 14, 2021 |
10-Q filing | 270.9M shares outstanding |
270M | 57M |
| Dec 07, 2020 |
S-1/A filing: This is an amendment to a registration statement providing information on recent sales of unregistered securities including common shares, preferred shares, warrant issuances, and option grants. |
N/A | 57M |
| Nov 20, 2020 |
S-1 filing: This document provides information on recent sales of unregistered securities, including common shares, preferred shares, warrants, and share options, as well as the consideration received for these securities. It also details the terms of a license agreement between The University of British Columbia and AbCellera Biologics Inc. |
N/A | 4.1M |